Dr. Anne Chiang presented at #WCLC in Seoul as a discussant for the exciting primary results of the Phase 3 ARTEMIS-008 trial, debated optimal use of therapeutic agents in #SCLC, and saw a friendly face!
@iaslc.bsky.social
@yalecancer.bsky.social
@yalecancer.bsky.social
@cancertherapyadv.bsky.socialNew research from #WCLC:
TAISHAN-302: Tambotatug Pelitecan Improves OS, PFS as Second-Line Treatment for Relapsed #SCLC 🫁
Presented this weekend at the @iaslc.bsky.social 2026 #WCLC and published in @NEJM
Read the full article: https://bit.ly/4h0XR3x
@medchemexpress.bsky.social💊 #WCLC 2026 | Key Advances in #LungCancer Research
From B7-H3 ADCs to next-generation TKIs and combination strategies, WCLC 2026 highlights evolving approaches in #NSCLC and #SCLC:
🔗https://bit.ly/4xW10sT
@newsen.bsky.socialLatest MAVERICK Trial Results Favor MRI Surveillance for Small-Cell Lung Cancer Management without Irradiation #South_Korea #Seoul #SCLC #MAVERICK #MRI_Surveillance
@newsen.bsky.socialLatest Phase III Trial: Tam-Peli Offers Hope for Small-Cell Lung Cancer Patients #South_Korea #Seoul #SCLC #Tam-Peli #TAISHAN-302
@newsen.bsky.socialPhase III Trial Demonstrates Breakthrough in Small-Cell Lung Cancer Treatment with Risvutatug Rezetecan #South_Korea #Seoul #SCLC #Risvutatug #ARTEMIS-008
@lungcancereurope.bsky.social🧠 Phase 3 MAVERICK results at #WCLC26 could change care for small cell #lungcancer.
MRI surveillance alone protected cognitive outcomes vs adding preventive brain radiotherapy, with no significant diff in survival so far.
If confirmed, this could spare some people with #SCLC unnecessary treatment.
@oncoalert.bsky.socialThe 🚨 OncoAlert TOP 10 — #WCLC26 🌐
👉Advanced #SCLC & #Mesothelioma 🇰🇷
We’re kicking off our OncoAlert TOP 10 for #WCLC26 with a focus on Advanced Small Cell #LungCancer ( #SCLC ) and Mesothelioma🫁
@lungcancereurope.bsky.socialMissed our #SCLC webinar, or want to revisit the discussion?
Watch the replay of Fast diagnosis, fragmented support: living with small-cell #lungcancer in Europe.
We’ve also added answers to audience Qs, including those we couldn’t cover live.
@oncoalert.bsky.social
@newsen.bsky.socialSignificant Survival Improvement in Extensive Stage Small Cell Lung Cancer with IMDELLTRA and IMFINZI Combination #USA #Thousand_Oaks #SCLC #IMDELLTRA #IMFINZI
@lancetrespirmed.bsky.social📰 New Series from The Lancet and The Lancet Respiratory Medicine, launched 7th September at #ERS2026
Therapeutics in Lung Cancer www.thelancet.com/series-do/lu...
The Series includes three review papers on early stage #NSCLC, advanced NSCLC, and #SCLC
🔓All content is free to access for all
@estroradiotherapy.bsky.socialMyth vs. Fact in Small Cell #LungCancer! 💡
For #WRAD2026, Dr Nicolas Pourel breaks down modern #SCLC treatment: #IMRT/#VMAT, low side effects, dose escalation & #ImmunoOncology.
🎥 Watch: https://bit.ly/467gmhZ
#Radonc #LungCancer
@sigtrans-sttt.bsky.socialWho benefits most from consolidation #Immunotherapy in limited-stage #SCLC?
Integrating #ctDNA status with tumor shrinkage identifies high-risk patients deriving survival benefit, while sustained ctDNA negativity predicts favorable outcomes.
@cancergrace.bsky.social@lungcancereurope.bsky.social200+ people have registered for today’s #SCLC webinar. There’s still time to join us.
We’ll hear from people living with SCLC and others affected by it, alongside clinicians, about diagnosis, treatment and support.
15:00 CEST / 14:00 BST